Available for logged-in reporters only
Newswise Vanessa and Brian are typical first-time parents. They adore their 3-year-old daughter, Adeline (Addie for short), and take much pride and pleasure in watching her learn to speak and assert her personality.
Addie is very friendly, Vanessa says. She loves being around other kids, spending time at the park and playing princess dress-up.
In most ways, Addie appears to be a normal toddler. However, Addies young life is far from typical. At 5-months-old Addie was diagnosed with Embryonal Tumor with Multilayered Rosettes (ETMR), a serious brain tumor primarily affecting children under 4-years-old. ETMR has less than a 10 percent survival rate.
The first few months of Addies life were uneventful, as she developed normally. Then in December 2016, Vanessa and Brian found themselves at the Pediatric Emergency Department at Joseph M. Sanzari Childrens Hospital at Hackensack Meridian Health Hackensack University Medical Center with baby Addie. She was unable to stay awake, vomiting and severely dehydrated. After performing several tests, including a CT scan, the physicians discovered a 5-centimeter mass in Addies brain.
Emergency surgery was performed, and Addie spent the next 12 days in the Pediatric Intensive Care Unit (PICU). I had a feeling that something was wrong. When the news came it was devastating. I didnt stop crying the entire time she was hospitalized. We really didnt know what to do, recalls Vanessa.
Vanessa and Brian first met Derek Hanson, M.D., section chief of pediatric neuro-oncology at the Joseph M. Sanzari Childrens Hospital, in the PICU.
He visited us every day that we were there. He stayed and spoke to us. He made us feel as comfortable as possible, Vanessa says.
Once the tumor was identified as ETMR, Dr. Hanson knew he had to think outside the box.
Looking back on previously reported cases of ETMR, it was clear that aggressive treatment alone would not lead to success, he says. Instead of hitting Addies tumor hard, I knew we needed to hit it smart and attack the underlying biologic mechanisms that were key to the tumor.
Dr. Hanson reviewed published research on ETMR and found a preclinical drug screen that identified the most effective chemotherapy agents used to treat an ETMR cell line.
I then created a modified treatment plan for Addie using surgery, chemotherapy and stem cell transplant, he says. If this new treatment regimen were to work, Addie would still be at very high risk for relapse. Therefore, following the completion of her upfront treatment, she began an 18-month maintenance chemotherapy regimen with DFMO, a drug we are currently using in a clinical trial to combat neuroblastomas.
Dr. Hansons new protocol proved to be successful. After undergoing four rounds of chemotherapy and a stem cell transplant, and receiving the experimental drugs, Addie received her first clean scan in September 2017. To date, her scans remain cancer free.
Vanessa and Brian are incredibly grateful to Dr. Hanson and his perseverance.
We could tell that he was personally invested and really cared, Vanessa says. When Addie was first diagnosed, we wanted the best treatment. Ultimately we stayed at Hackensack because Dr. Hanson found the best treatment for her. He was very willing to collaborate with Brian and I and make us part of the care team. He gave us options and consulted with others.
Its obvious that Addie is a fan, too. Vanessa recalls coming to the hospital for Addies speech therapy, and Addie insisting on visiting Dr. Hanson. He came and gave her a hug. It made her day! Vanessa says.
Recently, Addie finished her drug trial and now her family is taking more steps toward having a typical routine.
It feels scaryits not real yet, Vanessa says. After 26 months of chemo and all of the treatments, it is scary to think we are done. We are hopeful that this will be over.
Addie does have some side effects from treatment. Most significantly is a hearing loss that is treated with hearing aids and speech therapy. She is delayed in some of her gross motor skills, but recently learned to run.
After being given the news that your child is most likely going to die, every single day and every single milestone is that much more important and special. We cant take anything for granted. It taught us to be happy with the small things and value family and friendships, Vanessa says.
Addies response to the chemotherapy treatment showed that a biology-based treatment approach can be successful in ETMR, says Derek Hanson, M.D. Now we are looking to make this biological approach available to more children with ETMR.
Tackle Kids Cancer (a philanthropic initiative of Hackensack Meridian Health to raise money for pediatric cancer research and patient care programs) is funding the launch of an international registry and research platform for children with ETMR.
The registry will collect clinical information from ETMR patients from across the globe and available tumor specimens, Dr. Hanson says. This information will serve as a resource for physicians and researchers to improve our understanding of ETMR and develop better approaches to treatment and overall care of children with ETMR.
Addies mom, Vanessa, stresses the importance for research funding.
When we received the prognosis, there was no treatment protocol for ETMR. There are so many rare tumors that need more research. It is not acceptable in this day and age that a child is given a less than 10 percent chance because there is not enough research, she says. Cancer is not as rare as we all like to think it is. It is so important because these kids deserve a chance. Our kids deserve better than that.
The 2019-2020 Best Childrens Hospital rankings by U.S. News & World Report ranked the combined cancer program at Hackensack Meridian Healths two childrens hospitals Joseph M. Sanzari Childrens Hospital and K. Hovnanian Childrens Hospital #44 in the U.S. and the only cancer program in New Jersey to be ranked among the top 50 in the nation. In addition, the Joseph M. Sanzari Childrens Hospital at Hackensack University Medical Center is ranked #49 and the only childrens hospital in New Jersey to be ranked in Neurology and Neurosurgery.
To learn about Tackle Kids Cancer visit http://www.tacklekidscancer.org
Signs of Cancer in Children
Several symptoms could indicate cancer in kids, though many of them are also indicative of other health issues. These include paleness, easy bruising and unexplained, persistent fever. Learn more at http://www.HMHforU.org/CancerInKids.
Learn about Hackensack Meridian Healths commitment to compassionate, personalized cancer care for children at http://www.HMHforU.org/PediatricCancer.
Hackensack Meridian Health is a leading not-for-profit health care organization that is the largest, most comprehensive and truly integrated health care network in New Jersey, offering a complete range of medical services, innovative research and life-enhancing care.
Hackensack Meridian Health comprises 17 hospitals from Bergen to Ocean counties, which includes three academic medical centers Hackensack University Medical Center in Hackensack, Jersey Shore University Medical Center in Neptune, JFK Medical Center in Edison; two childrens hospitals - Joseph M. Sanzari Childrens Hospital in Hackensack, K. Hovnanian Childrens Hospital in Neptune; nine community hospitals Bayshore Medical Center in Holmdel, Mountainside Medical Center in Montclair, Ocean Medical Center in Brick, Palisades Medical Center in North Bergen, Pascack Valley Medical Center in Westwood, Raritan Bay Medical Center in Old Bridge, Raritan Bay Medical Center in Perth Amboy, Riverview Medical Center in Red Bank, and Southern Ocean Medical Center in Manahawkin; a behavioral health hospital Carrier Clinic in Belle Mead; and two rehabilitation hospitals - JFK Johnson Rehabilitation Institute in Edison and Shore Rehabilitation Institute in Brick.
Additionally, the network has more than 500 patient care locations throughout the state which include ambulatory care centers, surgery centers, home health services, long-term care and assisted living communities, ambulance services, lifesaving air medical transportation, fitness and wellness centers, rehabilitation centers, urgent care centers and physician practice locations. Hackensack Meridian Health has more than 35,000 team members, and 7,000 physicians and is a distinguished leader in health care philanthropy, committed to the health and well-being of the communities it serves.
The networks notable distinctions include having four hospitals among the top in New Jersey by U.S. News and World Report. Other honors include consistently achieving Magnet recognition for nursing excellence from the American Nurses Credentialing Center and being named to Beckers Healthcares 150 Top Places to Work in Healthcare/2019 list.
The Hackensack Meridian School of Medicine at Seton Hall University opened in 2018, the first private medical school in New Jersey in more than 50 years, welcomed its second class of 96 students in 2019 to its On3 campus in Nutley and Clifton. Additionally, the network partnered with Memorial Sloan Kettering Cancer Center to find more cures for cancer faster while ensuring that patients have access to the highest quality, most individualized cancer care when and where they need it.
Hackensack Meridian Health is a member of AllSpire Health Partners, an interstate consortium of leading health systems, to focus on the sharing of best practices in clinical care and achieving efficiencies.
For additional information, please visit http://www.HackensackMeridianHealth.org.
- Study Finds Racial and Ethnic Disparities in Treatment of AL Amyloidosis - DocWire News - November 22nd, 2020
- New Virtual Reality Tool, Domestic Cats are SARS-CoV-2 Carriers, Combination Therapy Advances: COVID-19 Updates - Bio-IT World - November 22nd, 2020
- SEE | Smoking worsens Covid-19 infection in the airways, new study reveals - Health24 - November 22nd, 2020
- Could Cell Therapy Be The Answer To COVID-19? - CBS Boston - November 3rd, 2020
- CA Prop 14 Explained: What To Know Before You Vote Election Day - Los Angeles, CA Patch - November 3rd, 2020
- GMP Cell Banking Services Market Predicted to Accelerate the Growth by 2019-2029 - TechnoWeekly - November 3rd, 2020
- Making Progress Against Relapsed/ Refractory DLBCL Without CAR T - OncLive - November 3rd, 2020
- Orchard Therapeutics to Host Virtual R&D Investor Event on Friday, November 13, 2020 - GlobeNewswire - November 3rd, 2020
- Editorial Article: Combating cancer: The incubation technology accelerating CAR-T cell therapy development - SelectScience - October 31st, 2020
- Richters Transformation: When a Slow-Growing Cancer Turns Aggressive - SurvivorNet - October 31st, 2020
- Detroit Pistons, Make-A-Wish put a smile on the face of Commerce Township boy - The Oakland Press - October 31st, 2020
- NexImmune Establishes Research Initiative with City of Hope to Focus on Novel Immunotherapeutic Approaches to Acute Myeloid Leukemia - Yahoo Finance - October 31st, 2020
- HBS and Harvard's Department of Stem Cell and Regenerative Biology Receive $25 Million Gift from The Chris and Carrie Shumway Foundation to Support... - October 23rd, 2020
- Harnessing regeneration of retinal tissues: An option almost within reach - Ophthalmology Times - October 23rd, 2020
- Fate Therapeutics' and Celyad's CAR therapies in oncology offer potential - pharmaceutical-technology.com - October 23rd, 2020
- World Wide Stem Cell Treatment Centers Provides Exceptional Regenerative Treatment Options To Those in Need - GlobeNewswire - October 16th, 2020
- Proposition 14: Stem cell research bonds City Times - City Times - October 16th, 2020
- BrainStorm Announces Financial Results for the Third Quarter of 2020 and Provides a Corporate Update - PRNewswire - October 16th, 2020
- How a UCSF team is giving Cronutt the sea lion a second chance with neuroscience - University of California - October 16th, 2020
- Caliber Pain is Featured as a 2020 Top NYC Patient Rated Pain Management Practice by Find Local Doctors - PR Web - October 10th, 2020
- Report of the president: Appointments and promotions | Stanford News - Stanford University News - October 10th, 2020
- UTSW Scientist: 'We Need More Women Thinking Creatively in the Lab and Pushing Science Forward' - dallasinnovates.com - October 10th, 2020
- Here's what is known about Trump's COVID-19 treatment - Science Magazine - October 4th, 2020
- Election Guide: Here's What You Need to Know About Proposition 14 - NBC Bay Area - October 4th, 2020
- ASX up 2.3%, banks and energy outperform - The Sydney Morning Herald - October 4th, 2020
- Autologous Stem Cell and Non-Stem Cell Based Therapies MARKET 2020 |INDUSTRY ANALYSIS, SIZE, SHARE, TRENDS, MARKET DEMAND, GROWTH, OPPORTUNITIES AND... - September 25th, 2020
- Finding The Achilles Heel of A Killer Parasite - Newswise - September 25th, 2020
- SHE Initiative Shines Light on Gender Disparities in Oncology Workforce - Targeted Oncology - September 25th, 2020
- Actinium Pharmaceuticals Successfully Completes First Dosing Cohort in the Phase 1 Study of Actimab-A and Venetoclax Combination Therapy in... - September 23rd, 2020
- Advances in the Treatment of Mantle Cell Lymphoma are Greatly Improving the Long-Term Outlook for Patients - Curetoday.com - September 23rd, 2020
- CytoDyn's Phase 2 Study of Leronlimab for Mild-to-Moderate COVID-19 Selected for Oral Presentation at the Special isirv-AVG Virtual Conference on... - September 23rd, 2020
- Opdivo (nivolumab) Demonstrated Superior Disease-Free Survival in Patients with Resected Esophageal or Gastroesophageal Junction Cancer Compared to... - September 23rd, 2020
- Coronavirus Researchers Discover How COVID-19 May Trigger Fatal Levels of Lung Inflammation - SciTechDaily - September 21st, 2020
- The Holistic Sanctuary Announces Exciting Plans to Expand Over Next 4 Years and Save More Lives - PRNewswire - September 21st, 2020
- Robert E. Windsor, MD, is being recognized by Continental Who's Who - PRNewswire - September 21st, 2020
- City of Hope Enters Licensing Agreement With Chimeric to Develop Its Pioneering Chlorotoxin CAR T Cell Therapy - Business Wire - September 21st, 2020
- Emerging immunotherapies in multiple myeloma - The BMJ - September 21st, 2020
- ADC Therapeutics Submits Biologics License Application to the U.S. Food and Drug Administration for Loncastuximab Tesirine for Treatment of Relapsed... - September 21st, 2020
- Oakland 24-year-old seeking multiethnic bone marrow donor - The Jewish News of Northern California - September 21st, 2020
- First-Line Treatment With Merck's KEYTRUDA (pembrolizumab) Doubled Five-Year Survival Rate (31.9%) Versus Chemotherapy (16.3%) in Certain Patients... - September 21st, 2020
- Coronavirus, Charity, and the Trolley Problem - Crooked - September 12th, 2020
- Targeted Approach Considered for the Treatment of Accelerated/Blast Phase MPNs - Targeted Oncology - September 1st, 2020
- Royal Biologics Announces the Acquisition of FIBRINET - PRNewswire - September 1st, 2020
- Novel Targets Outside of JAK Inhibition Inching into Myelofibrosis Treatment Landscape - Targeted Oncology - September 1st, 2020
- MaaT Pharma to Announce Clinical Data with its Lead Microbiota Biotherapeutic in Intestinal Acute GvHD at Virtual 46th Annual Meeting of the European... - August 28th, 2020
- The Inside Story Of Biotechs Barnum And His Covid Cures - Forbes - August 28th, 2020
- Mustang Bio: Slow, Steady Progress Towards Multiple Gene And CAR-T Therapy Goals - Seeking Alpha - August 25th, 2020
- Study sheds light on why retinal ganglion cells are vulnerable to glaucoma - Jill Lopez - August 19th, 2020
- Coronavirus Thursday update: UMN announces new stem cell treatment - TwinCities.com-Pioneer Press - August 15th, 2020
- Health and Fitness: Hip replacement surgery: getting back to what you love - taosnews - August 14th, 2020
- How MC Hammer And Other Performing Artists Are Sharing Their Love Of Science - Forbes - August 12th, 2020
- Chromosomal Rearrangements Associated with Chemotherapeutic Drug Resistance | McDonnell Boehnen Hulbert & Berghoff LLP - JD Supra - August 8th, 2020
- Chinese Govt-Compensated Experts Plead Guilty to Thieving Investigation From an American Childrens Medi ... - 90Xtra - August 7th, 2020
- US government considers ethics of aborted tissue research - Angelus News - August 7th, 2020
- Mesa Discusses Treating Myelofibrosis and Other MPNs - Targeted Oncology - August 7th, 2020
- Startup Accelerator: Volumetric Aims to Be the Tissue Bioprinting Farm of the Future - 3DPrint.com - August 6th, 2020
- Cord blood offers hope for rare diseases and ethnic minorities - The Province - August 6th, 2020
- FDA touts advanced manufacturing to address Covid-19 shortfalls - Endpoints News - August 5th, 2020
- Cancer Research Institute Awards $30.2 Million in Grants and Fellowships to Support Basic and Clinical Research in Immunology and Cancer Immunotherapy... - August 5th, 2020
- RenovaCare Appoints Dr. Lydia M. Evans to Its Board of Directors and Increases Board Membership - GlobeNewswire - August 4th, 2020
- MediVet Biologics Rebrands as Ardent Animal Health - Benzinga - August 3rd, 2020
- Church Point Police Captain dies from COVID-19 complications: 'Go and protect the heavens, my dearest friend' - The Advocate - August 1st, 2020
- BMT survivor study finds significant breast cancer risk in young women who received total body irradiation - The Mix - July 31st, 2020
- Hyperbaric Oxygen Therapy Can Enhance Cognition in Healthy Older Adults - PsychCentral.com - July 29th, 2020
- The surprising recovery with stem cells of 26 COVID-19 patient in Hidalgo - Explica - July 29th, 2020
- Johnny Tabaie is proud to announce the most powerful Stem Cell Therapy - Press Release - Digital Journal - July 29th, 2020
- COVID-19 Fibroblast Based Cell Therapy Candidate Shown to Reduce Lung Scarring in Aggressive Animal Model - El Paso Inc. - July 25th, 2020
- 'Self-eating' process of stem cells may be the key to new regenerative therapies - 7thSpace Interactive - July 23rd, 2020
- R3 International Now Including Exosomes with Stem Cell Therapy Program for Autism in Mexico - PR Web - July 23rd, 2020
- CAR T-Cell Therapy Offers Potential Solution for Relapse in MCL, But With Toxicity Risk - Targeted Oncology - July 22nd, 2020
- Fine-tuning adoptive cell therapy for advanced cancers - Newswise - July 22nd, 2020
- Global Cart Cell Therapy Market To Grow At A CAGR of 29.4% With The Emergence Of Immunotherapies In Medical Treatment - GlobeNewswire - July 22nd, 2020
- In Remission for 10 Years: Long-term Data on CAR-T Therapy - Medscape - July 21st, 2020
- MRFR predicts an Upsurge in the Leukemia Therapeutics Market valuation to USD 10.7 billion by 2023 - Jewish Life News - July 21st, 2020
- Cannabis Found Effective to Treat Sickle Cell Disease Pain - The Weed Blog - July 20th, 2020
- End of Palestinian Authority coordination with Israel in response to annexation threat: decision already impacting medical referrals - occupied... - July 20th, 2020
- Addiction Treatment Market Survey Report 2020 Stats and Forecasts to 2026 - Cole of Duty - July 18th, 2020
- 13 Promising Covid Treatments Emerging from Israel - The Jewish Voice - July 15th, 2020
- New Clues from Fruit Flies about the Critical Role of Sex Hormones in Stem Cell Control - Newswise - July 15th, 2020
- Impact of Covid-19 on Preimplantation Genetic Testing Market is Projected to Grow Massively in Near Future - Cole of Duty - July 13th, 2020